Clinical implications of seropositive and seronegative autoantibody status in rheumatoid arthritis patients: A comparative multicentre observational study
Nevin Hammam, Passant N. El-Husseiny, Suzan S. Al-Adle, Nermeen Samy, Nora Y. Elsaid, Dina F. El-Essawi, Eman F. Mohamed, Samar M. Fawzy, Samah A. El Bakry, Maha Nassr, Samah I. Nasef, Hanan M. El-Saadany, Shereen Elwan, Nada M. Gamal, Abdelhfeez Moshrif, Osman Hammam
TL;DR
This study compares disease characteristics in rheumatoid arthritis patients based on their autoantibody status, finding that dual antibody-positive patients have higher disease activity and risk of metabolic syndrome.
Contribution
The study provides new insights into how autoantibody status correlates with disease severity and metabolic syndrome in rheumatoid arthritis patients.
Findings
Dual seropositive RA patients show higher disease activity and functional impairment.
Dual seropositive patients have a higher risk of developing metabolic syndrome.
Single RF positivity is associated with fibromyalgia and longer disease duration.
Abstract
Rheumatoid factor (RF) and anti-cyclic citrullinated protein (anti-CCP) have been used to improve the diagnosis and prognosis of rheumatoid arthritis (RA). However, their association with RA disease phenotypes, individually and in combination, is not well studied. The aim of the study was to compare patients’ and disease characteristics, activity and severity in double seronegative (DNRA), single seropositive RF, single seropositive anti-CCP and double seropositive (DPRA) patients. Adults subjects with RA from Egyptian College of Rheumatology (ECR) database who had RF and anti-CCP results available were included. Demographic, clinical features, disease activity score 28 (DAS28), Health Assessment Questionnaire (HAQ) and laboratory data were collected and compared among different RA groups. 5268 RA patients with mean age of 44.9±11.6 years, and 4477 (85%) were females. 2900 (55%) had…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
| Parameter Mean ±SD or | Rheumatoid arthritis patients | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| Seropositive rheumatoid arthritis ( | ||||||
|
| ||||||
| All ( | DNRA ( | DPRA ( | RF+/anti-CCP- ( | anti-CCP+/RF- ( | ||
|
| ||||||
| Age (years) | 44.9 ± 11.6 | 43.8 ± 12.2 | 45.6 ± 11.3a | 45.2 ± 12a | 42.5 ± 10.9b,c | <0.0001 |
| Female | 4477 (85) | 770 (87.6) | 2416 (83.3)a | 764 (85.7) | 527 (88.3)b | 0.001 |
| Body mass index | 28.6±5.3 | 28.4 ± 5.6 | 28.8 ± 5.2 | 28.4 ± 5.3a | 27.8 ± 5.5b | 0.02 |
| Smoking | 402/3625 (11.1) | 73/572 (12.8) | 218/2076 (10.5) | 84/604 (13.9) | 27/369 (7.3)a,c | 0.006 |
|
| ||||||
| Diabetes mellitus | 418/5038 (8.3) | 76/873 (8.7) | 229/2701 (8.5) | 66/889 (7.4) | 47/575 (8.2) | 0.8 |
| Hypertension | 592/5038 (11.8) | 90/873 (10.3) | 317/2701 (11.7) | 118/889 (13.2) | 67/575 (11.7) | 0.3 |
| Metabolic syndrome | 297/1824 (16.3) | 38/265 (14.3) | 207/1074 (19.3) | 30/324 (9.3)b | 22/161 (13.7) | <0.0001 |
| HCV infection | 37/5038 (0.7) | 2/873 (0.2) | 16/2701 (0.6) | 17/889 (1.9)a,b | 2/575 (0.4)c | <0.0001 |
| Bronchial asthma | 26/5038 (0.5) | 5/873 (0.6) | 13/2701 (0.5) | 6/889 (0.7) | 2/575 (0.4) | 0.8 |
| Thyroid dysfunction | 83/5038 (1.7) | 14/873 (1.6) | 52/2701 (1.9) | 12/889 (1.4) | 5/575 (0.9) | 0.7 |
| Parameter Mean ±SD or | Rheumatoid arthritis patients | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| Seropositive rheumatoid arthritis ( | ||||||
|
| ||||||
| All ( | DNRA ( | DPRA ( | RF+/anti-CCP- ( | anti-CCP+/RF- ( | ||
| Disease duration | 6.37 ± 5.5 | 5.8 ± 5.5 | 6.5 ± 5.4 a | 6.8 ± 5.8 a | 6.03 ± 5 c | <0.0001 |
| Age at onset | 38.5 ± 11.1 | 38.1 ± 11.5 | 39.2 ± 10.8 | 38.3 ± 11.9 | 36.5 ± 10.3a,b,c | <0.0001 |
| Arthritis | 2339/2859 (81.8) | 351/461 (76.1) | 1344/1551 (86.7)a | 419/553 (75.8)b | 225/294 (76.5)b | <0.0001 |
| RA nodules | 287/3008 (9.5) | 44/446 (9.9) | 161/1771 (9.1) | 38/449 (8.5) | 44/342 (12.9) | 0.2 |
| Mucous ulcers | 67/1145 (5.9) | 13/143 (9.1) | 26/681 (4.1) | 8/199 (4)a | 18/122 (14.8)b,c | <0.0001 |
| Ocular | 571/3118 (18.3) | 113/507 (22.3) | 285/1710 (16.7)a | 106/554 (19.1) | 67/347 (19.3) | 0.03 |
| Sjogren’s syndrome | 492/3187 (15.4) | 75/449 (16.7) | 272/1899 (14.3) | 94/488 (19.3)b | 51/351 (14.5)b | 0.05 |
| Neurological manifestations | 267/2945 (9.1) | 52/414 (12.6) | 142/1761 (8.1)a | 52/467 (11.1) | 21/303 (6.9)a | 0.006 |
| Vasculitis | 68/2502 (2.7) | 10/341 (2.9) | 43/1534 (2.8) | 6/369 (1.6) | 9/258 (3.5) | 0.5 |
| Gastrointestinal manifestations | 635/2472 (25.7) | 96/401 (23.9) | 312/1382 (22.6) | 163/450 (36.2)a,b | 64/239 (26.8)c | <0.0001 |
| Cardiovascular manifestations | 333/3180 (10.5) | 76/525 (14.5) | 158/1740 (9.1)a | 63/562 (11.2) | 36/353 (10.2) | 0.005 |
| Pulmonary manifestations | 453/3154 (14.4) | 75/462 (16.2) | 239/1840 (12.9) | 82/507 (16.2) | 57/345 (16.5) | 0.08 |
| Osteoporosis | 37/5038 (0.7) | 2/873 (0.2) | 24/2701 (0.9) | 8/889 (0.9) | 3/575 (0.5) | 0.2 |
| Fibromyalgia | 446/2025 (22) | 51/298 (17.1) | 219/1101 (19.9) | 101/376 (26.9)a,b | 75/250 (30)a,b | <0.0001 |
| Renal manifestations | 150/2899 (5.2) | 31/454 (6.8) | 79/1622 (4.9) | 25/506 (4.9) | 15/317 (4.7) | 0.4 |
| Anemia | 873/1389 (62.9) | 88/182 (48.4) | 630/914 (68.9)a | 76/140 (54.3)b | 79/153 (51.6)b | <0.0001 |
| DAS28 | 4.4 ± 1.4 | 4.4 ± 1.5 | 4.4 ± 1.4 | 4.4 ± 1.4 | 4.3 ± 1.4 | 0.2 |
| HAQ | 0.9 ± 0.6 | 0.9 ± 0.7 | 1.0 ± 0.6 | 0.9 ± 0.6 | 0.8 ± 0.5b | 0.01 |
| Parameter Mean ±SD or | Rheumatoid arthritis patients | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| Seropositive rheumatoid arthritis (n=4389) | ||||||
|
| ||||||
| All ( | DNRA ( | DPRA ( | RF+/anti-CCP- ( | anti-CCP+/RF- ( | ||
| Hb (g/dL) | 11.5 ± 1.4 | 11.7 ± 1.4 | 11.4 ± 1.3a | 11.6 ± 1.5b | 11.7 ± 1.4b | <0.0001 |
| TLC×103 (cell/mm3) | 6.9 ± 2.3 | 6.9 ± 2.6 | 6.9 ± 2.3 | 6.9 ± 2.3 | 7.1 ± 2.3 | 0.5 |
| Platelets×103 (cell/mm3) | 294.2 ± 92.4 | 286 ± 83.1 | 298.2 ± 95.8a | 288.1 ± 91.3b | 297.3 ± 90.1 | 0.004 |
| ESR (mm/1st hour) | 44.1 ± 27.9 | 41.2 ± 25.9 | 45.8 ± 29.4a | 45.7 ± 26.4a | 38.6 ± 24.9b,c | <0.0001 |
| Positive CRP | 3139/4220 (74.4) | 427/597 (71.5) | 1896/2490 (76.14) | 494/649 (76.12) | 322/484 (66.5)b, c | <0.0001 |
| ALT (U/L) | 24.4 ± 13.9 | 24 ± 20.9 | 24.8 ± 12.9 | 24.3 ± 11.4 | 23.0 ± 10.8 | 0.2 |
| AST (U/L) | 25.8 ± 13.1 | 25.3 ± 17.8 | 26.6 ± 12.6 | 24.6 ± 10.9 | 24.1 ± 12.3 | 0.001 |
| Urea (mg/dL) | 23.6 ± 16.2 | 23.1 ± 17.5 | 23.2 ± 17.2 | 25 ± 13.7 | 22.8 ± 14.9 | 0.4 |
| Creatinine (mg/dL) | 0.8 ± 0.3 | 0.75 ± 0.3 | 0.76 ± 0.2 | 0.77 ± 0.2 | 0.76 ± 0.2 | 0.6 |
| SUA (mg/dL) | 4.7 ± 1.3 | 4.5 ± 1.5 | 4.7 ± 1.2 | 4.6 ± 1.4 | 4.9 ± 1.5 | 0.04 |
| Lipid profile: | ||||||
| Cholesterol (mg/dL) | 197.1 ± 65.8 | 192.6 ± 67.9 | 204.4 ± 61.7 | 169.2 ± 78.9a,b | 199.6 ± 54.9c | <0.0001 |
| LDL (mg/dL) | 102.3 ± 40.7 | 105.3 ± 44.2 | 107.1 ± 36.6 | 90.0 ± 47.7 | 100.9 ± 33.2 | <0.0001 |
| HDL (mg/dL) | 56.7 ± 30.9 | 58.4 ± 33.8 | 56.6 ± 27.8 | 53.5 ± 34.2 | 60.7 ± 32.2 | 0.1 |
| Triglycerides (mg/dL) | 122.6 ± 55.8 | 117.7 ± 61.1 | 137.3 ± 52.5a | 98.5 ± 55.2a,b | 112.6 ± 43.4b | <0.0001 |
| Parameter Mean ±SD or | Rheumatoid arthritis patients | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| Seropositive rheumatoid arthritis (n=4389) | ||||||
|
| ||||||
| All ( | DNRA ( | DPRA ( | RF+/anti-CCP- ( | anti-CCP+/RF- ( | ||
| Steroids | 3104/4425 (70.2) | 440/646 (68.1) | 1849/2560 (72.2) | 468/722 (64.8) | 347/497 (69.8)b | 0.01 |
| Methotrexate | 3383/4525 (74.8) | 494/663 (74.5) | 1984/2606 (76.1) | 510/737 (69.2)b | 395/519 (76.1)c | 0.002 |
| Leflunomide | 2024/4005 (50.5) | 306/543 (56.4) | 1160/2376 (48.8)a | 342/654 (52.3) | 216/432 (50) | 0.01 |
| Sulfasalazine | 156/434 (35.9) | 28/47 (59.6) | 13/37 (35.1)a | 23/42 (54.8)b | 13/37 (35.1) | <0.0001 |
| Cyclophosphamide | 43/2014 (2.1) | 5/282 (1.8) | 27/1219 (2.2) | 9/342 (2.6) | 2/171 (1.2) | 0.7 |
| Azathioprine | 48/2237 (2.2) | 9/301 (2.9) | 30/1372 (2.2) | 7/383 (1.8) | 2/181 (1.1) | 0.5 |
| Mycophenolate mofetil | 11/1984 (0.5) | 1/276 (0.4) | 5/1203 (0.4) | 5/338 (1.5) | 0/176 (0) | 0.08 |
| Cyclosporine A | 5/1863 (0.3) | 0/241 (0) | 4/1185 (0.3) | 0/298 (0) | 1/139 (0.7) | 0.4 |
| Biologics | 354/3095 (11.4) | 46/401 (11.5) | 225/1895 (11.9) | 57/477 (11.9) | 26/322 (8.1) | 0.3 |
| Colchicine | 35/1875 (1.9) | 8/247 (3.2) | 19/1188 (1.6) | 4/299 (1.3) | 4/141 (2.8) | 0.2 |
| Variables | Double positive | RF+/anti-CCP- | RF-/anti-CCP+ | |||
|---|---|---|---|---|---|---|
|
|
|
| ||||
| RRR (95%CI) | RRR (95%CI) | RRR (95%CI) | ||||
| Double negative | Ref | Ref | Ref | |||
| Age | 1.03 (1.00, 1.05) | 0.029 | 1.00 (0.98, 1.03) | 0.677 | 1.01 (0.98, 1.04) | 0.615 |
| Sex (Male) | 1.59 (0.64, 3.97) | 0.311 | 0.87 (0.29, 2.63) | 0.806 | 1.48 (0.51, 4.27) | 0.465 |
| Disease duration | 1.06 (0.99, 1.12) | 0.077 | 1.08 (1.01, 1.16) | 0.017 | 0.98 (0.91, 1.07) | 0.680 |
| Smoking | 1.62 (0.29, 9.18) | 0.584 | 3.91 (0.59, 26.10) | 0.159 | 1.76 (0.25, 12.56) | 0.573 |
| Arthritis | 0.87 (0.38, 2.07) | 0.744 | 0.74 (0.31, 1.75) | 0.492 | 0.63 (0.25, 1.61) | 0.338 |
| Ocular | 1.57 (0.55, 4.50) | 0.399 | 1.59 (0.51, 4.98) | 0.424 | 1.23 (0.33, 4.5) | 0.757 |
| CVS | 1.08 (0.37, 3.17) | 0.891 | 0.42 (0.10, 1.74) | 0.232 | 1.44 (0.39, 5.29) | 0.581 |
| FMS | 1.88 (0.84, 4.20) | 0.122 | 2.54 (1.10, 5.88) | 0.028 | 0.92 (0.32, 2.63) | 0.882 |
| MetS | 6.02 (0.74, 48.67) | 0.092 | 4.22 (0.46, 38.78) | 0.204 | 1.05 (0.06, 18.03) | 0.975 |
| DAS28 | 1.51 (1.20, 1.90) | <0.001 | 1.16 (0.90, 1.49) | 0.240 | 1.10 (0.84, 1.45) | 0.491 |
| Steroid use | 2.41 (1.36, 4.25) | 0.002 | 0.93 (0.48, 1.78) | 0.831 | 0.99 (0.49, 2.02) | 0.990 |
| MTX use | 0.29 (0.13, 0.65) | 0.003 | 0.49 (0.20, 1.20) | 0.119 | 0.50 (0.19, 1.33) | 0.166 |
| LFN use | 0.56 (0.31, 0.99) | 0.046 | 1.16 (0.59, 2.26) | 0.661 | 0.93 (0.45, 1.90) | 0.842 |
| Anemia | 1.54 (0.86, 2.74) | 0.143 | 1.30 (0.68, 2.46) | 0.420 | 0.99 (0.49, 2.01) | 0.998 |
| PLT | 1.00 (0.98, 1.00) | 0.703 | 0.99 (0.99, 1.00) | 0.476 | 1.00 (0.99, 1.00) | 0.233 |
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsHydrology and Watershed Management Studies · Flood Risk Assessment and Management · Meteorological Phenomena and Simulations
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterized by arthritis and subsequent destruction.^[1]^ The diverse spectrum of RA is associated with female predominance.^[2]^ RA is characterized by the production of autoantibodies, rheumatoid factor (RF) and anti-cyclic citrullinated protein (anti-CCP), that provide clues to the underlying disease pathophysiology. RF, an autoantibody directed against the Fc part of IgG, is an important serological marker for the diagnosis of RA in everyday clinical practice. During the last decade, multiple antibodies have been identified in RA against the citrullinated peptides including IgG, IgA, IgM.^[3]^ Anti-CCP has been emerging as a highly specific marker in RA diagnosis and prognosis.^[4]^ Both tests are sensitive; however, anti-CCP is more specific for RA diagnosis.^[5]^ The presence of RF positivity or anti-CCP is incorporated and weighed in the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for RA.^[6]^
Researchers have confirmed the significance of RF and anti-CCP for the early diagnosis of RA^[7]^ and disease activity evaluation.^[8]^ Despite this rising importance of autoantibodies in RA, there has been substantial discrepancy whether seropositive RA has more severe disease spectrum compared to seronegative RA. Higher disease activity and impaired physical function in double seropositive RA (RA and anti-CCP) at baseline, in addition to more radiographic progression has been described.^[9]^ In contrast, others reported severer activity^[10]^ and radiographic progression in seronegative RA.^[11]^ Bizzaro et al.^[12]^ found that anti-CCP levels were highly related to early RA but not to age and gender. Egyptian RA patients with high titers of RF and anti-CCP were associated with impairment in the physical function and higher steroid doses compared to those with low titers.^[13]^
Both of these antibodies, singly or in combination, may be representatives of different RA specific diseases features and drug responsiveness. Thus, anti-CCP and RF are providing potential different RA disease phenotypes. The aim of the current work was to assess the frequency of positive RF and anti-CCP singly or in combination, and to explore the clinical profile (demographic factors, disease characteristics, activity and severity, and laboratory features) associated with each antibody status RA groups: single-positive RF, single-positive anti-CCP, double-positive RF+/anti-CCP+ (DPRA) and double negative RA (DNRA). Factors associated with seropositive status were also well thought out.
Patients and Methods
This study is a multicentre observational study of the Egyptian College of Rheumatology-RA study group (ECR-RA) study, which has been described in detail elsewhere.^[2]^ Adult patients with RA were recruited between September 2018 till December 2021. Data were extracted from the ECR-RA database for patients with diagnosis of RA (N = 10, 364) confirmed using the 2010 ACR/EULAR classification criteria.^[6]^ Patients with missing RF or anti-CCP data were excluded (N = 5096). Patients provided informed consents to participate, and the ECR-RA study was approved by the Scientific Research and Ethical Committee and in accordance to the 1964 Helsinki declaration.
All patients were subjected to full history taking and clinical examination including body mass index (BMI). Patients’ demographic data including age, sex and disease characteristics as well as systems involved were collected. The major clinical features of RA including arthritis, mucous ulcer, ocular features (keratoconjunctivitis sicca, episcleritis, scleritis), neurologic manifestations (depression, peripheral neuropathy), vasculitis (cutaneous, system vasculitis), gastrointestinal manifestations (abdominal pain, hepatomegaly, elevated transaminase, autoimmune hepatitis), cardiovascular manifestations (pericarditis/pericardial effusion, myocarditis, endocarditis, valvular insufficiency), chest manifestations (pleurisy/pleural effusion, pulmonary infiltrates), and renal manifestations (proteinuria, hematuria, elevated serum creatinine).
The disease activity score-28 (DAS-28)^[14]^ and health assessment questionnaire (HAQ)^[15]^ were assessed. Comorbidities, such as diabetes mellitus, hypertension, metabolic syndrome (MetS), hepatitis C virus (HCV), thyroid dysfunction and bronchial asthma were recorded. Current medications use including synthetic disease modifying anti-rheumatic drugs (DMARDs), in addition to steroids were recorded. The laboratory investigations including complete blood count (CBC), liver and kidney function tests, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and lipid profile panel were recorded. RF and anti-CCP presence were determined.
Patients were grouped according to the autoantibodies (RF and anti-CCP) status; DNRA was defined as absence of both RF and anti-CCP; DPRA was defined as presence of both RF and anti-CCP, single-positive RF and single-positive anti-CCP.
Statistical analysis
It was performed using Stata statistical software version 15 (Stata-Corp). Descriptive analyses were performed. Continuous variables were expressed as means (standard deviations), or medians (interquartile range). Categorical variables were expressed as absolute numbers and percentages. Patients in different groups were compared using One-way analysis of variance (ANOVA) or chi-square as appropriate, followed with pairwise comparisons of means to compute all differences of means of variables between individual groups. Multinomial logistic regression analysis was performed to determine independent variables that would predict single and double positivity autoantibody status. Results are summarized as relative risk ratios (RRR) and confidence intervals (CI). Two-sided p-values were considered significant at < 0.05.
Results
The characteristics and comparisons between each RA subgroups according to RF and anti-CCP status are presented in tables 1, 2, 3, and 4. A total of 5268 patients from the ECR-RA database were included in the study, mean age was 44.9±11.6 years, and 4477 were females (85%) and 791 were males (15%). The mean DAS28 and HAQ scores were 4.4±1.4 and 0.9±0.6 respectively. 2900 (55%) had DPRA, 892 (16.9%) had single positive RF, and 597 (11.3%) single positive anti-CCP. Both antibodies were negative in 879 (16.7%) of the patients.
Patients with single positive anti-CCP were younger (42.5 years) compared to other groups (P < 0.001). Female: male ratio was varied between groups; however, the frequency of males was significantly higher in DPRA (P = 0.001). Smoking was significantly more frequent in single positive RF group (P = 0.006). Further demographic characteristic information for each RA group is provided in Table 1.
Tables 1 and 2 lists the significant differences of the most important clinical and laboratory features between each RA groups. Patients with single positive anti-CCP were younger (42.5 years) and had an earlier age of disease onset (36.5 years) compared to other groups (P < 0.001). Patients with DPRA had significantly higher frequency of MetS (19.3%, P < 0.001), arthritis (68.7%, P < 0.001), anemia (68.9%, P < 0.0001), and functional impairment (P = 0.01). The percentage of patients with ocular (22.3%), central nervous system (12.6%) and cardiovascular disease (14.5%) were significantly more frequent in DNRA (P = 0.03, P = 0.0006 and P = 0.005 respectively). Among discordant antibody status, with only one antibody positive, patients with either positive anti-CCP or RF presented with higher fibromyalgia syndrome (30% and 26.9% respectively, P < 0.0001); however, patients with single positive RF presented with higher gastrointestinal diseases (36.2%, P < 0.0001) and HCV (P < 0.0001).
The percentage of patients with steroids use was higher among DPRA patients (72.2%, P = 0.01); while those with DNRA were most likely to use sulfasalazine (59.6%, P < 0.001). Patients with single positive RF were less likely to use methotrexate (69.2%, P = 0.002)(Table 4).
Table 5 summarizes the multinomial logistic regression. Patients with older age (RRR: 1.03, 95%CI: 1.0, 1.0, P = 0.029), greater DAS28 (RRR: 1.51, 95%CI: 1.2, 1.9, P < 0.001), higher steroid use (RRR: 2.4, 95%CI: 1.36, 4.25, P = 0.002) were at higher odds of DPRA, while, subjects with lower MTX (methotrexate) (RRR: 0.29, 95%CI: 0.13, 0.65, P = 0.003) and leflunomide (RRR: 0.56, 95%CI: 0.31, 0.99, P = 0.046) use were at lower risk of falling into the DPRA group. Subjects with longer disease duration (RRR: 1.08, 95%CI: 1.01, 1.16, P = 0.017), and FMS (fibromyalgia) (RRR: 2.54, 95%CI: 1.10, 5.88, P= 0.028) were associated with higher odds of RF+/ anti-CCP-status.
Discussion
The field of autoantibodies has brought major insights in rheumatology. It resulted in better understanding of the pathophysiology in RA and the development of the new 2010 ACR/ EULAR classification for RA. Although autoantibodies, RF and anti-CCP, have prognostic significance in RA;^[4]^ their relation to other disease characteristics remains a debate. The disease phenotype in seronegative and seropositive RA has been previously presented; though comparing groups in view of single-positive serology (RF or anti-CCP), double-negative and double-positive serology has not been thoroughly examined. This work is a large multicentre observational study including 5268 adult RA patients who had results of RF and anti-CCP available, recruited from the ECR-RA study database. A key objective was to compare demographic, clinical, laboratory features, disease activity and severity of Egyptian RA patients across RA groups with different autoantibodies status (DPRA, DNRA, single positive RF and anti-CCP).
In the current study, patients with DPRA clearly showed higher disease activity and severity in regards to those with dual negative antibodies status. Additionally, markers of systemic inflammation including ESR, CRP, platelet count were significantly higher in patients with DPRA versus others, denoting more aggressive disease. In line, high disease activity and impaired physical function were reported in RF+/anti-CCP+ versus seronegative RA patients.^[9]^ In consistency, DAS-28, ESR and CRP were significantly higher in patients with DPRA versus DNRA, single positive RF and anti-CCP.^[16]^ Anti-CCP is associated with greater disease activity and poorer remission rates.^[17]^ The DAS-28 was comparable among seronegative (double negative for RF and anti-CCP) and seropositive patients; however, more joint damage was reported with seropositive RA.^[18]^ Conversely, significantly higher DAS-28, HAQ score, more radiographic progression and slower response to treatment were reported in negative RF/anti-CCP versus positive RF/anti-CCP.^[19]^ Conflicting results are reported regarding the impact of RF versus anti-CCP positivity on disease activity; anti-CCP positive patients had lowest disease activity and disability regardless RF status; and achieved faster remission.^[20]^
The presence of autoantibodies is a distinctive feature of RA. Several studies have indicated the clinical relevance of RF and anti-CCP antibodies in RA. High titers of RF have been associated with more aggressive articular disease, and higher prevalence of extra-articular manifestations, especially when in combination with ACPA.^[16,21,22]^ In the present study, ocular manifestations were found to be higher in patients with DNRA (22.3%). In previous studies, there was no relationship between RF and ocular surface involvements.^[23,24]^ However, there was a significant association between the presence of anti-CCP and ocular manifestations related to RA.^[25]^ Patients with either positive anti-CCP or RF presented with higher fibromyalgia syndrome, which is also indicative of clinical active disease. Positivity of RF and anti-CCP was evaluated between patients with or without FMS in RA patients. Rheumatoid factor was positive in 67.9% and 75.5% and anti-CCP was positive in 71.7% and 76.5% of the patients with or without FMS, respectively (P > 0.05).^[26]^ The current study indicates that there is no significant association between neurological manifestations in patients with RA and autoantibodies positivity. In some cases, but not all, the presence of ACPA and RF autoantibodies can be detected in the pathologic analysis of neurologic lesions in patients with RA.^[27]^ In the current study, presence of mucous ulcer was significantly higher in patients with anti-CCP antibodies. Recent data are suggestive of a role for mucosal surfaces in the development of auto-immune responses (autoantibodies production) associated with the development of RA.^[28]^ Indeed differences in RA-patients with and without RF) and anti-CCP have been observed such as differences in clinical presentations.
In the current work, patients with single positive anti-CCP were significantly younger and had an earlier age of disease onset compared to other groups. Significant association between gender and seropositivity was found with female pre-dominance across all groups. On regression, older age was significantly associated with DPRA. It is widely accepted that RA encompasses great heterogeneity. Both antibodies may represent different RA diseases with specific courses and drug responsiveness. Therefore, RF and anti-CCP cannot be used synonymously or interchangeably as they represent different disease entities.
In the current work, MetS was the most prevalent comorbidity in DPRA (19.3%). On comparing seronegative and sero-positive RA patients, hypertension, type II diabetes and dyslipidemia were the most frequent comorbidities and similar. ^[29]^ Currently, significant association was found between the type of RA and comorbidities in which MetS was significantly more frequent in DPRA. In addition, the extra-articular manifestations that often determine the severity and comorbidity of RA are also closely associated with anti-CCP positivity.^[30]^ Both anti-CCP and RF have been found to associate with cardiovascular disease and mortality in RA patients.^[31]^ In contrast to the current work, others showed akin results on comparing seronegative and seropositive RA regarding co-morbidities.^[19]^ The traditional cardiovascular disease (CVD) risk factors were significantly associated with single positive RA, in which BMI, LDL (low-density lipoprotein), cholesterol and triglycerides were significantly higher in DPRA patients.
However, surprisingly CVD occurred in 14.5% of double negative RA which was significantly higher compared to other groups. In contrast, no significant difference was found on comparing seropositive and seronegative RA regarding the 10-year CVD risk.^[18]^ It has been proposed that the autoantibodies might contribute to CVD burden; in which anti-CCP antibodies have been associated with long-term mortality and worse CVD outcomes in non-RA patients.^[32]^ However, the heightened inflammatory state could accelerate the process of atherosclerosis and subsequent CVDs.^[33]^ The traditional CVD risk factors account only for 50% of total CVD risk in RA patients;^[34]^ implying the strong interplay between inflammation, atherogenesis and CVDs.
As already stated before, RFs are detectable in non-rheumatic conditions as well. The frequency of RF positive individuals in infectious diseases depend on whether it is a primary or secondary infection. In the current work, HCV infection was significantly more frequent in single positive RF patients. In line, 50%–70% of patients with HCV infection have positive RF antibodies, while anti-CCP was not observed; limiting the diagnostic utility of RF in HCV-related arthropathy.^[35]^ The estimated prevalence for HCV globally is 3%;^[36]^ however, exceptionally in Egypt, it is estimated to be 10%–15%.^[37]^ Lymphotropism which is a prominent feature of HCV-infection is characterized by stimulation of the immune system resulting in autoantibodies production as RF and cryoglobulins.^[38]^
The significance of the current work is boosted by the fact that it is among few studies investigating the effect of concordant presence of both RF anti-CCP and its impact on disease phenotype. The autoantibodies have several pathogenic potentials through immune complex formation and their binding to Fc receptor on the macrophages which promotes subsequent tumor necrosis factor (TNF) production;^[39]^ and through complement activation.^[40]^ Additionally, anti-CCP antibodies stimulate production of neutrophil extracellular traps (NETs) which trigger a proinflammatory state through enhancing production of cytokines and adhesion molecules in RA.^[41]^ Interestingly, immune-complex assays showed that adding RF IgM boosted the capacity of the anti-CCP to stimulate the macrophages resulting in increased cytokines production,^[16]^ highlighting the integration of both autoantibodies in RA inflammatory status. In line, the presence of several autoantibodies has been associated with an augmented inflammatory response in RA.^[42]^ It has been proposed that seronegative RA might require less aggressive treatment ^[43]^ and is not a mild disease phenotype.^[10,19]^
The cross-sectional study design is a limitation to find out a casual-relationship between the autoantibody status, disease characteristics and response to treatment. Liver function tests were significantly higher in patients with RF+/anti-CCP+ autoantibody status, which could be attributed to the greater use of methotrexate and leflunomide in DPRA. However, this is a leading large multicentre real-world study of Egyptian RA patients capable to detect small differences among different groups. Results need to be validated through larger scale longitudinal studies to prove causality. Additionally, different measures of disease activity as the clinical disease activity score were not explored; and no data have been collected regarding structural joint damage.
In conclusion, all the data together brought light on comparing different groups of RA patients based upon RF and anti-CCP autoantibody status. Patients with double seropositivity (RF+/ anti-CCP+) had more severe disease phenotype evidenced by the significantly increased markers of inflammation, increased frequency of arthritis, greater use of steroids and the more impairment in physical function. Current guidelines for initial therapy still do not promote to treat seropositive and seronegative RA differently. Considering tailored therapy for patients with both RF and anti-CCP may allow for better outcomes. However, in the current study CVD was significantly more frequent in DNRA in spite of the association of several traditional CVD risk factors with RF+/anti-CCP+, highlighting the considerable inflammatory and clinical burden of RF-/ anti-CCP-which might provide a better definition for this disease phenotype. This leaves an interesting area for further research, aiming to gain more knowledge.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Mc Innes IB Schett G.The pathogenesis of rheumatoid arthritis N Engl J Med.20113652205–22192215003910.1056/NEJ Mra 1004965 · doi ↗ · pubmed ↗
- 2Gheita TA Raafat HA El-Bakry S Aet al Rheumatoid arthritis study of the Egyptian College of Rheumatology (ECR): nationwide presentation and worldwide stance Rheumatol Int.202343667–6763661736210.1007/s 00296-022-05258-2PMC 9995404 · doi ↗ · pubmed ↗
- 3Verpoort KN Jol-van der Zijde CM Papendrecht-van der Voort E Aet al Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response Arthritis Rheum.2006543799–38081713356010.1002/art.22279 · doi ↗ · pubmed ↗
- 4Whiting Penny F Smidt Nynke Sterne Jonathan A Cet al Systematic review: accuracy of anti-citrullinated Peptide antibodies for diagnosing rheumatoid arthritis Ann Intern Med.2010152456–64W 155–W 4662036865110.7326/0003-4819-152-7-201004060-00010 · doi ↗ · pubmed ↗
- 5Sun Jianhong Zhang Yuhui Liu Leiet al Diagnostic accuracy of combined tests of anti cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis: a meta-analysis Clin Exp Rheumatol.20143211–2124050751 · pubmed ↗
- 6Aletaha D Neogi T Silman A Jet al 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative Arthritis Rheum.2010622569–25812087259510.1002/art.27584 · doi ↗ · pubmed ↗
- 7Qingmei C Yanfeng W Yuanyuan J.Clinical significance of combined anti-cyclic citrullinated peptide antibody and rheumatoid factor assays in rheumatoid arthritis diagnosis Arch Rheumatol.201530104–108
- 8Zendman A Jvan Venrooij WJ Pruijn GJ.Use and significance of anti-CCP autoantibodies in rheumatoid arthritis Rheumatology (Oxford).20064520–251618894610.1093/rheumatology/kei 111 · doi ↗ · pubmed ↗